SH5-07
CAS No. 1456632-41-9
SH5-07( SH-5-07 | SH 5-07 )
Catalog No. M11972 CAS No. 1456632-41-9
SH5-07 (SH-5-07, SH 5-07) is a potent, selective small-molecule STAT3 inhibitor with IC50 of 3.9 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 67 | Get Quote |
|
| 5MG | 110 | Get Quote |
|
| 10MG | 178 | Get Quote |
|
| 25MG | 312 | Get Quote |
|
| 50MG | 464 | Get Quote |
|
| 100MG | 672 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSH5-07
-
NoteResearch use only, not for human use.
-
Brief DescriptionSH5-07 (SH-5-07, SH 5-07) is a potent, selective small-molecule STAT3 inhibitor with IC50 of 3.9 uM.
-
DescriptionSH5-07 (SH-5-07, SH 5-07) is a potent, selective small-molecule STAT3 inhibitor with IC50 of 3.9 uM; preferentially inhibits Stat3:Stat3 DNA-binding activity, shows no inhibition of Stat1:Stat1 or Stat5:Stat5 activity; exerts pY705 Stat3 inhibition in human glioma, breast, and prostate cancer cells, blocks STAT3-dependent gene transcription along with Bcl-2, Bcl-xL, Mcl-1, cyclin D1, c-Myc, and survivin expression; decreases the proliferation and viability of glioma, breast, and prostate cancer cells and v-Src-transformed murine fibroblasts harboring constitutively active STAT3; effectively inhibits tumor growth in mouse xenograft models of glioma and breast cancer.
-
In VitroSH5-07 is a hydroxamic acid analog of BP-1-102. SH5-07 dose-dependently inhibits Stat3 activity with an IC50 of 3.9±0.6 μM in in vitro assay. It preferentially inhibits Stat3:Stat3 DNA-binding activity, ahead of inhibiting Stat1:Stat3 activity, with minimal effects on Stat1:Stat1 activity. SH5-07 binds Stat3, disrupts Stat3 association with growth factor receptor, and thereby inhibits Stat3 phosphorylation. It induces antitumor cell effects against malignant cells harboring constitutively-active Stat3. SH5-07 inhibits the expression of known Stat3-regulated genes. Bcl-2, Bcl-xL, c-Myc, Survivin, Cyclin D1 and Mcl-1 expression is reduced in response to 24 h, 5 μM SH5-07 treatment.
-
In VivoTail vein injection or oral gavage delivery of SH5-07 or SH4-54 inhibits growth of 90-150 mm3 established subcutaneous mouse xenografts of human glioma (U251MG) and breast (MDA-MB-231) tumors that harbor aberrantly-active Stat3, associated with decreased c-Myc, Mcl-1 and Cyclin D1 expression. No significant changes in body weights, blood cell counts, or the gross anatomy of organs, or obvious signs of toxicity are observed.
-
SynonymsSH-5-07 | SH 5-07
-
PathwayJAK/STAT Signaling
-
TargetSTAT
-
RecptorSTAT
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1456632-41-9
-
Formula Weight625.6068
-
Molecular FormulaC29H28F5N3O5S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESO=C(NO)C1=CC=C(N(CC2=CC=C(C3CCCCC3)C=C2)C(CN(C)S(=O)(C4=C(F)C(F)=C(F)C(F)=C4F)=O)=O)C=C1
-
Chemical NameBenzamide, 4-[[(4-cyclohexylphenyl)methyl][2-[methyl[(2,3,4,5,6-pentafluorophenyl)sulfonyl]amino]acetyl]amino]-N-hydroxy-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yue P, et al. Cancer Res. 2016 Feb 1;76(3):652-63.
molnova catalog
related products
-
Pimozide
Pimozide is an antipsychotic agent that acts as an antagonist of the D2, D3, and D4 receptors and the 5-HT7 receptor.
-
NT219
NT219 is a dual inhibitor of insulin receptor substrate 1/2 (IRS1/2) and STAT3, enhances the aggregation of misfolded prion protein NT219 affects the levels of certain molecular chaperones and inhibits STAT3 phosphorylation NT219 is useful for the study of cancer and neurodegenerative diseases.
-
Stattic
Stattic, the first nonpeptidic small molecule, potently inhibits STAT3 activation and nuclear translocation with IC50 of 5.1 μM, highly selectivity over STAT1.
Cart
sales@molnova.com